Fangda advised Micro-Tech (Nanjing) Co., Ltd. (688029.SH, “Micro-Tech”) on its acquisition of 51% of the issued share capital of Creo Medical S.L.U. (“CME”) from Creo Medical Group plc (“Creo”), through Micro-Tech’s wholly owned subsidiary, Micro-Tech (NL) International B.V. The closing of this acquisition became effective retroactively as of February 12, 2025, upon Creo’s receipt of the purchase price in the amount of approximately 36.72 million euros on February 14, 2025.

Micro-Tech is a leading company in the field of minimally invasive diagnostics and treatment, primarily engaging in the research, development, manufacturing, and sales of minimally invasive medical devices. CME is a medical device distribution channel company based in Spain, with subsidiaries in multiple European countries. It focuses on the distribution of medical devices in the fields of gastroenterology, urology, respiratory medicine, and single-use endoscopy. CME, previously wholly owned by Creo, became a controlled subsidiary of Micro-Tech after the closing. This acquisition is expected to further enhance Micro-Tech’s product sales capabilities and market share in Europe.

The transaction involves multiple European jurisdictions, including Spain, France, Belgium, and Germany. Fangda, as the leading counsel, provided comprehensive legal services to Micro-Tech throughout the process of this transaction, including coordinating with legal counsel across multiple European jurisdictions for due diligence and foreign direct investment clearance, drafting and negotiating transaction documents, and assisting with the closing. The Fangda team was led by partners Sherry Xu and Diana Li. Team members included Frank Feng, Jiaye Zhu, Janet Song, Sherlyn Qu and Esther Rao.